MDT

99.02

+1.44%↑

A

146.01

+0.06%↑

VEEV

218.99

-0.4%↓

HQY

89.13

+4.04%↑

NEOG

9.46

+2.94%↑

MDT

99.02

+1.44%↑

A

146.01

+0.06%↑

VEEV

218.99

-0.4%↓

HQY

89.13

+4.04%↑

NEOG

9.46

+2.94%↑

MDT

99.02

+1.44%↑

A

146.01

+0.06%↑

VEEV

218.99

-0.4%↓

HQY

89.13

+4.04%↑

NEOG

9.46

+2.94%↑

MDT

99.02

+1.44%↑

A

146.01

+0.06%↑

VEEV

218.99

-0.4%↓

HQY

89.13

+4.04%↑

NEOG

9.46

+2.94%↑

MDT

99.02

+1.44%↑

A

146.01

+0.06%↑

VEEV

218.99

-0.4%↓

HQY

89.13

+4.04%↑

NEOG

9.46

+2.94%↑

Search

Quidel Corp

Открыт

35.11 3.36

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

33.23

Макс.

35.05

Ключевые показатели

By Trading Economics

Сотрудники

6,600

Рекомендации

By TipRanks

Рекомендации

Нейтрально

Прогноз на 12 месяцев

-20.42% downside

Дивиденды

By Dow Jones

Следующий отчет о доходах

11 февр. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

305M

1.9B

Предыдущая цена открытия

31.75

Предыдущая цена закрытия

35.11

Quidel Corp График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

14 янв. 2026 г., 22:41 UTC

Приобретения, слияния, поглощения

Canadian Natural Resources, Tourmaline File Deal Notice With Antitrust Regulator

15 янв. 2026 г., 00:00 UTC

Отчет

Welcome to Greenland, an Economy Reliant on Subsidies and Shrimp -- WSJ

14 янв. 2026 г., 23:47 UTC

Обсуждения рынка

Oil Slips After Trump Appears to Tilt Away From Military Action in Iran -- Market Talk

14 янв. 2026 г., 23:44 UTC

Обсуждения рынка

Nikkei May Decline After Hitting Record Highs; Election in Focus -- Market Talk

14 янв. 2026 г., 23:39 UTC

Обсуждения рынка

ANZ's New Bull Still Sees Valuation Gap to Peers -- Market Talk

14 янв. 2026 г., 23:32 UTC

Обсуждения рынка

Gold Declines on Likely Technical Correction, Possible Profit-Taking -- Market Talk

14 янв. 2026 г., 22:56 UTC

Приобретения, слияния, поглощения

Soho House Amends Rollover and Support Agreements With Broad Street Principal Investments and Others

14 янв. 2026 г., 22:53 UTC

Приобретения, слияния, поглощения

Soho House: Apollo Global Management and Goldman Sachs Asset Management Amend Debt Commitment

14 янв. 2026 г., 22:17 UTC

Обсуждения рынка

Global Equities Roundup: Market Talk

14 янв. 2026 г., 22:17 UTC

Обсуждения рынка

WiseTech's Revenue Growth Drivers Attract Scrutiny -- Market Talk

14 янв. 2026 г., 22:09 UTC

Отчет

CITIC Securities: Uptrend in China Capital Markets Supported Results >600030.SH

14 янв. 2026 г., 22:08 UTC

Отчет

CITIC Securities 2025 Oper Rev CNY74.83B Vs. CNY58.12B >600030.SH

14 янв. 2026 г., 22:08 UTC

Отчет

CITIC Securities 2025 Net CNY30.05B Vs. Net CNY21.57B >600030.SH

14 янв. 2026 г., 21:53 UTC

Приобретения, слияния, поглощения

WuXi XDC Expects 2025 Net to Increase Over 38% on Year

14 янв. 2026 г., 21:53 UTC

Приобретения, слияния, поглощения

WuXi XDC Expects 2025 Revenue to Increase More Than 45% on Year

14 янв. 2026 г., 21:52 UTC

Приобретения, слияния, поглощения

WuXi XDC Announces Positive Profit Alert for 2025

14 янв. 2026 г., 21:51 UTC

Приобретения, слияния, поглощения

Citigroup Acting as Financial Advisor to WuXi XDC

14 янв. 2026 г., 21:51 UTC

Приобретения, слияния, поглощения

WuXi XDC: Aims to Keep Listing Status of BioDlink

14 янв. 2026 г., 21:51 UTC

Приобретения, слияния, поглощения

WuXi XDC: Company to Finance BioDlink Shares Acquisition via Internal Resources

14 янв. 2026 г., 21:50 UTC

Обсуждения рынка
Отчет

Financial Services Roundup: Market Talk

14 янв. 2026 г., 21:50 UTC

Обсуждения рынка

Basic Materials Roundup: Market Talk

14 янв. 2026 г., 21:49 UTC

Приобретения, слияния, поглощения

WuXi XDC: BioDlink Offer to Cost HK$2.79B

14 янв. 2026 г., 21:48 UTC

Приобретения, слияния, поглощения

WuXi XDC Offers to Pay HK$4.00 for Each BioDlink International Share

14 янв. 2026 г., 21:48 UTC

Приобретения, слияния, поглощения

WuXi XDC Makes Cash Offer for BioDlink International

14 янв. 2026 г., 21:13 UTC

Обсуждения рынка

Oil Retreats Late After Trump Comments on Iran -- Market Talk

14 янв. 2026 г., 20:30 UTC

Обсуждения рынка
Отчет

Danaher's Preliminary 4Q Seen as Promising -- Market Talk

14 янв. 2026 г., 20:13 UTC

Обсуждения рынка

U.S. Natural Gas Futures Sink Ahead of Storage Report -- Market Talk

14 янв. 2026 г., 20:08 UTC

Обсуждения рынка

Oil Futures Extend Rally on Iran Tensions -- Market Talk

14 янв. 2026 г., 19:33 UTC

Обсуждения рынка

Nutrien Seen as Winner in Tighter 2026 Potash Market, Higher Prices -- Market Talk

14 янв. 2026 г., 19:06 UTC

Обсуждения рынка
Отчет

Wells Fargo Says Customers, Economy Remain Resilient -- Market Talk

Сравнение c конкурентами

Изменение цены

Quidel Corp Прогноз

Целевая цена

By TipRanks

-20.42% падение

Прогноз на 12 месяцев

Средняя 26.5 USD  -20.42%

Максимум 31 USD

Минимум 22 USD

Основано на мнении 5 аналитиков Wall Street, спрогнозировавших целевые цены для Quidel Corp на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Нейтрально

5 ratings

1

Покупка

3

Удержание

1

Продажа

Финансовые показатели

$

О компании Quidel Corp

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
help-icon Live chat